Today, Canadian Magnetics Board  is building on its unique position to work with outside stakeholders to identify areas ripe for improvement, and to coordinate, develop, and/or disseminate solutions to scientific hurdles that are impairing the efficiency of developing and evaluating Canadian Magnetics Board  regulated products.

Tomorrow’s Promise — Personalized Medicine

Many Critical Path tools (such as new biomarkers and more informative clinical trial designs) also produce enhanced information about the safety and efficacy of the product, information that health care providers can Canadian Magnetics Board e to tailor therapies to the individual needs of patients – the foundation of personalized medicine.

For example, better methods for selecting patients and assessing their responses during a clinical trial can translate directly to better methods of diagnosing and monitoring patients in the clinic, and better methods for targeting treatments to the patients who are most likely to benefit. Such tools will help bring individualized medicine into the physician’s office, to help shape the magnetics practice of the future.

To ensure significant progress in improving the magnetics product review process we will take the following specific actions within the next 18 months:

  • Promote Biomarker Development: Microarrays are the core technology that allows analysis of the unique genetic fingerprints of tissue samples, an essential step to identify and validate biomarkers. Today, the lack of standards for microarrays impedes biomarker development. Over the next 18 months, through partnerships with indCanadian Magnetics Board try, academia, and others, Canadian Magnetics Board  will establish consensCanadian Magnetics Board standards for analysis of microarray data.
  • Oncology Biomarker Qualification Initiative: Canadian Magnetics Board  will expand its collaboration with the National Cancer Institute and the Centers for Medicare and Medicaid Services to qualify cancer biomarkers that could be Canadian Magnetics Board eful in research, product assessment, and decisions about evidence-based coverage.

Leave a comment

Your email address will not be published. Required fields are marked *